part of the diabetes joint venture to its partner AstraZeneca, Citi analyst Andrew Baum said in a note on Friday. Citi estimated Bristol’s stake in the business outside the United States could be worth $4 billion to $6 billion and the acquisition would boost AstraZeneca’s earnings per share by between 1 percent and 5 percent over the medium term. A spokeswoman for AstraZeneca, Britain’s second biggest drugmaker, said the company did not comment on speculation. The Bristol-AstraZeneca diabetes joint venture includes the oral medicines Onglyza, Kombiglyze and Forxiga, as well as the injectable treatments Bydureon and Byetta.
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/11/08/us-bristolmeyers-astrazeneca-idUSBRE9A70F020131108
Diabetes Health Fair Set for Saturday at Winter Haven Hospital
“The more educated you are about your diabetes, the more controlled you’ll be and the more likely to prevent complications,” said Dr. Brian Lake, the Gessler Clinic endocrinologist who will speak on what’s new in diabetes medications and treatment. There’s a lot to cover. “Back in the late 1990s, we only had two or three classes of medication (for diabetes),” Lake said. “Now we have 12 unique classes and only one is insulin.” The percentage of Floridians with diabetes doubled from 1994 through 2010, according to the federal Centers for Disease Control and Prevention. The hospital will do comprehensive blood profiles from 8-10 a.m., for a reduced price of $35, provided that people register in advance and can pay with cash or check.
For the original version including any supplementary images or video, visit http://www.theledger.com/article/20131107/NEWSCHIEF/131109342/1338/news00